Cognition Therapeutics (CGTX) Current Assets (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Current Assets data on file, last reported at $35.8 million in Q1 2026.

• Quarterly Current Assets rose 56.63% year-over-year to $35.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 56.63% YoY) and the FY2025 annual result came in at $48.0 million, up 62.38% from the prior year.
• Current Assets slipped to $35.8 million in Q1 2026 per CGTX's latest filing, from $48.0 million in the prior quarter.
• Across five years, Current Assets topped out at $56.4 million in Q1 2022 and bottomed at $19.0 million in Q2 2025.
• The 5-year median for Current Assets is $38.0 million (2024), against an average of $38.6 million.
• The widest annual swing landed in 2022, when Current Assets soared 407.39%; it then plunged 43.22% in 2025.
• Tracing CGTX's Current Assets over 5 years: stood at $47.6 million in 2022, then slipped by 28.18% to $34.2 million in 2023, then dropped by 13.64% to $29.6 million in 2024, then jumped by 62.38% to $48.0 million in 2025, then slipped by 25.37% to $35.8 million in 2026.
• Per Business Quant, the three latest CGTX Current Assets figures stand at $35.8 million (Q1 2026), $48.0 million (Q4 2025), and $42.9 million (Q3 2025).

Peer Comparison